Vitaly Margulis, M.D.
Upon completion of a B.S. degree in biology and biochemistry with highest honors at the University of Texas, and honors medical degree at The University of Texas Southwestern Medical School, I was accepted into a highly competitive urology residency at the University of Texas Southwestern Medical Center in Dallas. During residency training, additional research time was focused on minimally invasive techniques to manage small renal masses, evaluation of a novel approach to perform nephron sparing surgery utilizing radiofrequency ablation, and utilization of tissue micro-array technology to evaluate biomarkers as predictors of bladder cancer outcome. Upon completion of rigorous clinical training in urology, I have entered and completed urologic oncology fellowship at the MD Anderson Cancer Center, where my research focus was on understanding the molecular biology of renal cell carcinogenesis and progression as a model for developing novel diagnostic and therapeutic strategies for this disease. Specifically, our group investigated the role of TGF-beta signal transduction in human renal cell carcinoma with goals of developing targeted therapies. Current scientific endeavors include identification of novel biomarkers in renal cell carcinoma, which could potentially allow for timely diagnosis, staging, prognostication and identification of candidates for adjuvant systemic therapies.
|Medical School||UT Southwestern Medical Center (2001)|
|Internship||UT Southwestern Medical Center at Dallas (2002)|
|Residency||UT Southwestern Medical Center at Dallas (2006)|
|Fellowship||MD Anderson Cancer Center (2009)|
Predictors of oncologic outcome after resection of locally recurrent renal cell carcinoma
Margulis V, McDonald M, Matin SF, et al The Journal of Urology April 2009 Issue 4, Volume 181 496
Type III TGF-β Receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-β signaling pathway
Vitaly Margulis, Tapati Maity, Xiu-Ying Zhang, et. al Clinical Cancer Research September 2008 14 5722-5730
Genetic Susceptibility to Renal Cell Carcinoma: The Role of DNA Double Strand Break Repair Pathway
Margulis V, Lin J, Hushan Y, et al Cancer Epidemiology, Biomarkers & Prevention September 2008 17 2366
Surgical morbidity associated with administration of targeted molecular therapy prior to cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
Margulis V, Matin SF, Tannir N, et al The Journal of Urology July 2008 180, 1 94-98
Multi-institutional external validation of the predictive value of Ki-67 labeling index in patients treated with radical cystectomy
Margulis V, Karakiewicz P, Fradet Y, et al Journal of the National Cancer Institute January 2009 Volume 101, Number 2 114-119